For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

“To this end, we are encouraged by the fact that others have developed TYK2 inhibitors that have been tested in humans for ...

Researchers emulated target trials comparing recurrence of nephrolithiasis among patients with preexisting nephrolithiasis initiating SGLT-2 inhibitors vs an active comparator. (HealthDay News) — For ...

On the question of whether the benefits of sotagliflozin, an oral dual sodium-glucose co-transporter types 1 and 2 (SGLT1/SGLT2) inhibitor, outweigh the risks in this patient population, the committee ...

FSGS presents significant management challenges, with nephrologists (n=102) estimating that, on average, nearly half of their patients are not optimally managed with existing therapies. Spherix’s ...

Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney diseases ...

The stars are out for Game 5 of the 2024 World Series in Los Angeles. While prime-time names such as Shohei Ohtani and Aaron Judge compete on the field for the Los Angeles Dodgers and New York ...

A RECENT real-world study has found that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are more effective at reducing kidney complications in ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity. HealthDay News — From 2010 to 2023, there was an ...

MONDAY, Oct. 28, 2024 (HealthDay News) — From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) ...